171 related articles for article (PubMed ID: 24375391)
1. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.
Capdevila J; Meeker A; García-Carbonero R; Pietras K; Astudillo A; Casanovas O; Scarpa A
Cancer Metastasis Rev; 2014 Mar; 33(1):345-51. PubMed ID: 24375391
[TBL] [Abstract][Full Text] [Related]
2. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in neuroendocrine tumors.
Duque M; Modlin IM; Gupta A; Saif MW
JOP; 2013 Jul; 14(4):372-6. PubMed ID: 23846930
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.
Oberg K; Casanovas O; Castaño JP; Chung D; Delle Fave G; Denèfle P; Harris P; Khan MS; Kulke MH; Scarpa A; Tang LH; Wiedenmann B
Clin Cancer Res; 2013 Jun; 19(11):2842-9. PubMed ID: 23459719
[TBL] [Abstract][Full Text] [Related]
5. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
6. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
Raymond E; García-Carbonero R; Wiedenmann B; Grande E; Pavel M
Cancer Metastasis Rev; 2014 Mar; 33(1):367-72. PubMed ID: 24375390
[TBL] [Abstract][Full Text] [Related]
8. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents.
Papaxoinis G; Syrigos K; Saif MW
Discov Med; 2016 May; 21(117):391-402. PubMed ID: 27355335
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
Mulvey CK; Bergsland EK
Hematol Oncol Clin North Am; 2016 Feb; 30(1):63-82. PubMed ID: 26614369
[TBL] [Abstract][Full Text] [Related]
11. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
Raj N; Reidy-Lagunes D
Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
[TBL] [Abstract][Full Text] [Related]
12. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
Geis C; Fendrich V; Rexin P; Di Fazio P; Bartsch DK; Ocker M; Quint K; Heverhagen AE
J Surg Res; 2015 Apr; 194(2):388-393. PubMed ID: 25439321
[TBL] [Abstract][Full Text] [Related]
13. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
14. Medical treatment of neuroendocrine tumours.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.
Bartlett JM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S86-95. PubMed ID: 21115427
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
[TBL] [Abstract][Full Text] [Related]
18. The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.
De Dosso S; Grande E; Barriuso J; Castellano D; Tabernero J; Capdevila J
Cancer Metastasis Rev; 2013 Dec; 32(3-4):465-77. PubMed ID: 23589060
[TBL] [Abstract][Full Text] [Related]
19. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.
Cella CA; Minucci S; Spada F; Galdy S; Elgendy M; Ravenda PS; Zampino MG; Murgioni S; Fazio N
Cancer Treat Rev; 2015 Nov; 41(9):754-60. PubMed ID: 26142874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
